Skip to main content

Shah Pritesh's Form 4 filing

NovoCure Ltd (NVCR) · filed Mar 7, 2022

Accession no.
0001645113-22-000020
Filed
Mar 7, 2022
Trade date
Mar 3-4, 2022
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $402.1K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Shah PriteshCIK 0001744884Officer (Chief Commercial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 3, 2022Ordinary SharesAGrant or awardAcquired+21,714$0.00$095,226Direct
Mar 3, 2022Ordinary SharesSSaleDisposed−997$74.50−$74,276.594,229Direct
Mar 4, 2022Ordinary SharesSSaleDisposed−2,632$73.34−$193,030.8891,597Direct
Mar 4, 2022Ordinary SharesSSaleDisposed−1,914$70.41−$134,764.7489,683Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 3, 2022Ordinary SharesAGrant or awardAcquired+38,027$80.59+$3,064,595.9338,027Direct
Mar 3, 2022Ordinary SharesAGrant or awardAcquired+6,231$80.59+$502,156.296,231Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)